3 Mistakes To Avoid During Your Performance Review
3 Mistakes To Avoid During Your Performance Review
When we think of performance reviews, we usually assume it's all the manager's job. We just wait for their judgment of our work. But performance reviews should be a collaborative process. You have the opportunity to review your progress, highlight your wins, and be open about your goals and even struggles.
According to Gallup, however, only 20% of employees think their performance reviews motivate them to excel in their work. The good news? You can take control or at least play an active role for a more meaningful conversation with your boss. Here are some mistakes you can avoid during your performance review and leverage it to level up your career.
Not Being Prepared
Performance reviews are no ordinary events where you simply show up and listen. You should go there equipped with all the records you need to show your growth and achievements. Meeting your boss empty-handed means a missed opportunity for your career. So, before the review, have your brag sheet ready. List your wins, including those times you received commendations from big clients, exceeded the team's target, and mentored new members.
Don't forget to record those moments you've stepped up and led projects, solved recurring problems, or introduced new tools that increased the team's efficiency. By putting everything into writing, you can easily address your manager's questions or clarifications with real numbers and specific scenarios.
Speaking of questions, you should also prepare thoughtful responses. Anticipate being asked about your areas for improvement, action plans, and goals for the next quarter or year.
Your manager might also ask you about skills you want to develop, your experience with the team, and how else you can support each other. By reflecting on these questions, you can express your insights well. Prepare your own questions as well to gain more valuable input from your manager.
Not Selling Yourself
Being ready with your records is one thing; selling yourself is another. The latter is crucial, especially if you're eyeing a promotion or a raise. But even when you're not, you should still know how to advocate for yourself confidently and professionally. This can lead to more opportunities, like flexible schedules, better projects, and greater confidence from your boss.
So highlight your contributions to the team and how they made a difference. For example, you can say, 'I'm grateful to have helped increase the team's sales by 30% through personalized welcome and milestone packages, which made new and existing customers feel valued.'
Mention the kudos you received from colleagues, bosses, or clients. For instance, 'I'm honored to be praised by such a meticulous client who even committed to giving us more projects.' More than the flex, you're showing the value you bring to the team and how you can't be easily replaced.
Not Even Having One
Ideally, your manager should give you regular performance reviews. But this may not always be the case. In fact, 47% of employees get feedback only a few times a year or even less. A Gallup survey also showed that 95% of managers aren't happy with their performance review systems.
If the company you're in doesn't have an organized review system, or worse, doesn't do performance reviews at all, be proactive. Politely ask for a meeting with your manager, so you can talk about your progress, challenges, goals, and timelines. For example, you can say, 'I'm wondering if we could have a quick feedback session next week to make sure I'm aligned with the team's goals and expectations.'
It's not about being demanding but rather taking the initiative to stay on track with your responsibilities and long-term growth. Even without regular reviews, make sure to record informal feedback you've received along the way so you have something to start with.
Performance reviews may sometimes feel more discouraging than inspiring, but you can use them to your advantage with the right approach. Do not make the mistake of coming unprepared, not knowing how to sell yourself, or simply accepting the absence of a review. These evaluations are not threats but opportunities, so welcome them!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
43 minutes ago
- Washington Post
GOP tax bill would ease regulations on gun silencers and some rifles and shotguns
WASHINGTON — The massive tax and spending cuts package that President Donald Trump wants on his desk by July 4 would loosen regulations on gun silencers and certain types of rifles and shotguns, advancing a longtime priority of the gun industry as Republican leaders in the House and Senate try to win enough votes to pass the bill.
Yahoo
an hour ago
- Yahoo
Lake Street: AMT-130 Could Be Game-Changer For ClearPoint
uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V. (NASDAQ:QURE) regulatory update on AMT-130, an experimental gene therapy for Huntington's disease. A team of scientists in lab coats studying a microscope, working on developing gene therapy solutions. uniQure N.V. (NASDAQ:QURE) declared that it has partnered with the FDA to seek an expedited approval process for AMT-130. If the trials go well and the FDA approves it, Lake Street sees AMT-130 as maybe ClearPoint's first 'meaningful partner asset.' ClearPoint provides disposables valued at almost $20,000 for each AMT-130 infusion, suggesting a significant financial benefit associated with the therapy's effectiveness. The FDA's support might result in the approval by the end of 2026, which would have a big effect on ClearPoint's financial standing and confirm its strategic focus on image-guided neurosurgery and gene therapy delivery. According to Lake Street, this regulatory milestone increases clarity on ClearPoint's contribution to the advancement of clinical-stage gene treatments and provides further assurance regarding the clearance timeline for AMT-130. While we acknowledge the potential of QURE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It presented encouraging three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the EAACI Congress 2025. A lab scientist peering into a microscope focused on gene editing technology. All 10 patients were free of attacks and treatment for a median of 23 months after receiving a single dose of lonvo-z, which led to a 98% mean reduction in monthly HAE attacks. Positive safety results were maintained across all treatment dosages. The current Phase 3 HAELO trial has a majority of U.S. enrollment and has completed screening ahead of schedule. Intellia Therapeutics, Inc. (NASDAQ:NTLA) plans to launch in 2027 after submitting a BLA in 2026. Lonvo-z (NTLA-2002) is an experimental in vivo CRISPR-based gene editing therapy that targets the KLKB1 gene to prevent HAE attacks. The FDA has designated it as an Orphan Drug and RMAT, while the EMA has designated it as PRIME, among other regulatory classifications. Administered intravenously at doses ranging from 25 to 75 mg, the therapy demonstrated dose-dependent kallikrein protein decrease and long-term efficacy, with no major treatment-related side effects recorded. While we acknowledge the potential of NTLA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
